Tofacitinib is marketed under several brand names, with the most prominent being Xeljanz [1]. Other brand names for tofacitinib include Xeljanz XR [1].
What is Xeljanz used for?
Xeljanz is a prescription medication used to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is also used to treat polyarticular course juvenile idiopathic arthritis in patients two years of age and older [1]. Tofacitinib works by inhibiting Janus kinase (JAK) enzymes, which are involved in the signaling pathways that lead to inflammation [1].
When does the patent for Xeljanz expire?
The patent protection for tofacitinib, including its brand names like Xeljanz, is complex and involves multiple patents covering different aspects such as the compound itself, methods of use, and formulations. Information on specific patent expiry dates and ongoing patent litigation can be found through resources like DrugPatentWatch.com [2]. Patent expiry is a critical factor in determining when generic versions of the drug may become available.
Can generic versions of Xeljanz be sold?
The availability of generic versions of tofacitinib is contingent upon patent expiry and regulatory approvals. Once patents expire and if regulatory hurdles are cleared, generic manufacturers can seek approval to market their versions of the drug. This process can be influenced by patent challenges and exclusivity periods [2].
Who manufactures Xeljanz?
Xeljanz is manufactured by Pfizer Inc. [1]. Pfizer is a global pharmaceutical company responsible for the development, manufacturing, and marketing of the drug.